Scholarlink

Purpose <p>Total thyroidectomy (TT) remains the standard surgical treatment of sporadic medullary thyroid cancer (sMTC), primarily due to the presumed risk of occult contralateral disease. However, recent evidence suggests that in selected patients, hemithyroidectomy (HT) may offer comparable oncologic outcomes. This retrospective study aimed to evaluate the prevalence of occult contralateral disease and to identify clinicopathological factors associated with disease-free survival (DFS).</p> Methods <p>We retrospectively analyzed all surgical patients with sMTC at a tertiary academic center (2013–2025), excluding patients with hereditary MTC, RET mutations, or clinical evidence of MEN2. Kaplan-Meier analysis with logrank testing was used to identify predictors of DFS.</p> Results <p>Forty-eight patients were included (66.7% female, median age 60.5 years). TT was performed in 44 patients (91.7%). Bilateral disease was present in five patients (11.4%), all detected on preoperative ultrasound. No cases of occult contralateral disease were found. During a median follow-up of 3.4 years, seven patients (14.6%) experienced recurrence. Advanced T stage, nodal involvement, distant metastases, lymphatic and vascular invasion, extracapsular extension, and male sex were all significantly associated with reduced DFS (all <i>p</i> &lt; 0.05). Persistent postoperative calcitonin elevation (&gt; 2 pg/mL) strongly predicted recurrence (<i>p</i> &lt; 0.001), whereas baseline calcitonin &gt; 500 pg/mL did not.</p> Conclusion <p>Occult contralateral disease in sMTC is rare when high-quality preoperative ultrasound is available. In selected patients with unifocal, node-negative tumors and favorable pathology, HT combined with structured calcitonin monitoring may be an oncologically safe, less morbid alternative. These findings support individualized, risk-adapted surgical strategies in sMTC. Prospective validation is warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Is hemithyroidectomy enough? Low risk of occult contralateral disease in sporadic medullary thyroid cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月22日

查看全文
  • Andreas Spörlein,
  • Christoph Becker,
  • Joseph Berthelot,
  • Valentin Burkhardt,
  • Katharina Laubner,
  • Mira Fink,
  • Bernd Jänigen

摘要

Purpose

Total thyroidectomy (TT) remains the standard surgical treatment of sporadic medullary thyroid cancer (sMTC), primarily due to the presumed risk of occult contralateral disease. However, recent evidence suggests that in selected patients, hemithyroidectomy (HT) may offer comparable oncologic outcomes. This retrospective study aimed to evaluate the prevalence of occult contralateral disease and to identify clinicopathological factors associated with disease-free survival (DFS).

Methods

We retrospectively analyzed all surgical patients with sMTC at a tertiary academic center (2013–2025), excluding patients with hereditary MTC, RET mutations, or clinical evidence of MEN2. Kaplan-Meier analysis with logrank testing was used to identify predictors of DFS.

Results

Forty-eight patients were included (66.7% female, median age 60.5 years). TT was performed in 44 patients (91.7%). Bilateral disease was present in five patients (11.4%), all detected on preoperative ultrasound. No cases of occult contralateral disease were found. During a median follow-up of 3.4 years, seven patients (14.6%) experienced recurrence. Advanced T stage, nodal involvement, distant metastases, lymphatic and vascular invasion, extracapsular extension, and male sex were all significantly associated with reduced DFS (all p < 0.05). Persistent postoperative calcitonin elevation (> 2 pg/mL) strongly predicted recurrence (p < 0.001), whereas baseline calcitonin > 500 pg/mL did not.

Conclusion

Occult contralateral disease in sMTC is rare when high-quality preoperative ultrasound is available. In selected patients with unifocal, node-negative tumors and favorable pathology, HT combined with structured calcitonin monitoring may be an oncologically safe, less morbid alternative. These findings support individualized, risk-adapted surgical strategies in sMTC. Prospective validation is warranted.